Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Autolus Therapeutics

    NASDAQ: AUTL · Real-Time Price · USD
    2.35
    0.09 (3.98%)
    At close: Jun 06, 2025, 3:59 PM
    2.35
    0.21%
    After-hours: Jun 06, 2025, 05:43 PM EDT

    Autolus Therapeutics Statistics

    Share Statistics

    Autolus Therapeutics has 266.14M shares outstanding. The number of shares has increased by 0.03% in one year.

    Shares Outstanding

    n/a
    		 266.14M

    Shares Change (YoY)

    n/a
    		 0.03%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 63.26%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 22

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 10.59M, so 3.98% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 10.59M

    Short % of Shares Out

    n/a
    		 3.98%

    Short % of Float

    n/a
    		 5.24%

    Short Ratio (days to cover)

    n/a
    		 4.1

    Valuation Ratios

    The PE ratio is -2.72 and the forward PE ratio is -3.02. Autolus Therapeutics's PEG ratio is 0.1.

    PE Ratio

    n/a
    		 -2.72

    Forward PE

    n/a
    		 -3.02

    PS Ratio

    n/a
    		 59.25

    Forward PS

    n/a
    		 0.9

    PB Ratio

    n/a
    		 1.4

    P/FCF Ratio

    n/a
    		 -2.49

    PEG Ratio

    n/a
    		 0.1
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Autolus Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 10.88, with a Debt / Equity ratio of 0.12.

    Current Ratio

    n/a
    		 10.88

    Quick Ratio

    n/a
    		 10.81

    Debt / Equity

    n/a
    		 0.12

    Debt / EBITDA

    n/a
    		 -0.29

    Debt / FCF

    n/a
    		 -0.22

    Interest Coverage

    n/a
    		 -25.98

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $15,641.42

    Profits Per Employee

    n/a
    		 $-341,054.1

    Employee Count

    n/a
    		 647

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 2.75

    Taxes

    Income Tax

    n/a
    		 1.53M

    Effective Tax Rate

    n/a
    		 -0.7%

    Stock Price Statistics

    The stock price has increased by -47.2% in the last 52 weeks. The beta is 1.74, so Autolus Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.74

    52-Week Price Change

    n/a
    		 -47.2%

    50-Day Moving Average

    n/a
    		 1.47

    200-Day Moving Average

    n/a
    		 2.61

    Relative Strength Index (RSI)

    n/a
    		 80.27

    Average Volume (20 Days)

    n/a
    		 2,044,195

    Income Statement

    In the last 12 months, Autolus Therapeutics had revenue of 10.12M and earned -220.66M in profits. Earnings per share was -0.86.

    Revenue

    n/a
    		 10.12M

    Gross Profit

    n/a
    		 -1.27M

    Operating Income

    n/a
    		 -241.43M

    Net Income

    n/a
    		 -220.66M

    EBITDA

    n/a
    		 -182.42M

    EBIT

    n/a
    		 -209.84M

    Earnings Per Share (EPS)

    n/a
    		 -0.86
    Full Income Statement

    Balance Sheet

    The company has 227.38M in cash and 52.63M in debt, giving a net cash position of 174.75M.

    Cash & Cash Equivalents

    n/a
    		 227.38M

    Total Debt

    n/a
    		 52.63M

    Net Cash

    n/a
    		 174.75M

    Retained Earnings

    n/a
    		 -1.1B

    Total Assets

    n/a
    		 746.34M

    Working Capital

    n/a
    		 549.16M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -206.27M and capital expenditures -34.82M, giving a free cash flow of -241.09M.

    Operating Cash Flow

    n/a
    		 -206.27M

    Capital Expenditures

    n/a
    		 -34.82M

    Free Cash Flow

    n/a
    		 -241.09M

    FCF Per Share

    n/a
    		 -0.94
    Full Cash Flow Statement

    Margins

    Gross margin is -12.52%, with operating and profit margins of -2385.63% and -2180.45%.

    Gross Margin

    n/a
    		 -12.52%

    Operating Margin

    n/a
    		 -2385.63%

    Pretax Margin

    n/a
    		 -2165.36%

    Profit Margin

    n/a
    		 -2180.45%

    EBITDA Margin

    n/a
    		 -1802.61%

    EBIT Margin

    n/a
    		 -2385.63%

    FCF Margin

    n/a
    		 -2382.31%

    Dividends & Yields

    AUTL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AUTL is $10, which is 342.5% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $10

    Price Target Difference

    n/a
    		 342.5%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.67

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist